Clemson University

TigerPrints
All Theses

8-2013

The Development of a Rapid Fiber-Based
Immunoassay as a Point-of-Care or In-Home
Diagnostic Test
Christopher Waddell
Clemson University, c.ryan.waddell@gmail.com

Follow this and additional works at: https://tigerprints.clemson.edu/all_theses
Part of the Biomedical Engineering and Bioengineering Commons
Recommended Citation
Waddell, Christopher, "The Development of a Rapid Fiber-Based Immunoassay as a Point-of-Care or In-Home Diagnostic Test"
(2013). All Theses. 1724.
https://tigerprints.clemson.edu/all_theses/1724

This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for inclusion in All Theses by an authorized
administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.

Theses

THE DEVELOPMENT OF A RAPID FIBER-BASED IMMUNOASSAY AS A POINTOF-CARE OR IN-HOME DIAGNOSTIC TEST

A Thesis
Presented to
the Graduate School of
Clemson University

In Partial Fulfillment
of the Requirements for the Degree
Master of Science
Bioengineering

by
Christopher Ryan Waddell
August 2013

Accepted by:
Dr. Alexey Vertegel, Committee Chair
Dr. Konstantin Kornev
Dr. Agneta Simionescu

Abstract
Early diagnosis of conditions allows for physicians to treat patients earlier, and
ultimately improve patient outcomes. Two conditions of particular interest for earlier and
cheaper diagnosis are the influenza virus and human immunodeficiency virus (HIV).
Antiviral treatment administered within the first 48 hours of influenza infection decreases
symptom severity, risk of complications, and reduced healthcare costs. Early diagnosis of
HIV can decrease the risk of transmission of the virus to HIV negative individuals and
allow for earlier administration of highly active antiretroviral treatment (HAART),
improving patient quality of life and patient outcomes.
Currently, the “gold standard” for detection of both Influenza and HIV are tests
performed in a clinical laboratory setting. There are rapid diagnostic tests that can be
performed at the point-of-care or an in-home setting, but these tests have their limitations.
This study aims to develop a highly sensitive, nanofiber-based immunochromatography
assay for the detection of such conditions at the point-of-care or an in-home setting.
Electrospun CA/PMMA/PEO nanofiber yarns were prepared and shown to be a viable
substrate for antibody attachment and detection of conditions. Colloidal gold-labeled
antibodies were prepared to detect analyte in a solution, allowing for detection of an
analyte visible to the naked eye. Furthermore, several immunoassay systems were
successfully developed using each of these components. These immunoassay systems
have potential for employment either at the point-of-care or as in-home diagnostic tools
to allow for earlier diagnosis.
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Chapter 1
1 Introduction
Early diagnosis of conditions allows physicians to better and more accurately treat
patients to improve patient outcomes [1]. For patients infected with the influenza virus,
earlier antiviral treatment, within the first 48 hours, leads to decreased symptom severity
and risk of complications [2-4]. The conventional “gold standard” for influenza diagnosis
is viral cell culture [5-8]. This diagnostic method; however, requires a long turn-around
time and its complexity requires it to be performed in a clinical laboratory setting rather
than at the point-of-care. More recently, rapid influenza diagnostic tests (RIDTs) have
gained traction for diagnosis of influenza at the point-of-care [5-9]. However, the
sensitivity of these tests is lacking in some cases and they are not employed for an inhome diagnostic setting [10-13].
Human immunodeficiency virus (HIV) is a serious and chronic viral infection.
Like influenza, early highly active antiretroviral treatment (HAART) administration
improves patients’ quality of life, longevity, and reduces the risk of virus transmission
[14-17]. The “gold standard” for HIV diagnosis is the HIV enzyme immunoassay (EIA)
[14]. However, this methodology requires a long turn-around time for results, has a high
complexity requiring testing in a clinical laboratory setting, and may give false negative
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results at certain time-points. These diagnostic tests also incur high costs that limit
availability to those in low-resource settings [14, 16, 18-20]. There are several rapid HIV
diagnostic tests currently available, one of which has been approved for in-home use by
the patient.
Chapter 2 begins by providing a brief overview of immunology, specifically the
immune system, antibody structure, function, and interaction with biomolecules. The
influenza virus and treatment are then briefly discussed, followed by an overview of
current diagnostic testing approaches. Clinical and financial considerations of the human
immunodeficiency virus are then discussed along with current HIV testing strategies.
Finally, a review of diagnostic testing methodologies is presented, including a brief
explanation of the clinical laboratory improvement amendments law (CLIA). The
principles of immunoassays, employed in immunochromatography, fluorescence
immunoassays and immunohistochemistry, are reviewed along with other clinical
laboratory diagnostic methods. The literature review concludes mentioning in-home
diagnostic tests that are currently available.
Electrospun polymeric nanofiber yarns have been shown to have high specific
surface area, useful for surface modification and use in various fields, including biosensor
applications. Chapter 3 discusses the preparation and functionalization of electrospun
nanofiber yarns for employment in an immunoassay system. Current over-the-counter
diagnostic tests apply the immunochromatography principle using gold nanoparticles to
provide the signal read by the end-user. The preparation and characterization of colloidal
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gold-labeled antibodies for use as an optical label for analytes is presented in Chapter 4,
followed by the development of an immunochromatographic assay utilizing the
aforementioned yarns and gold-labeled antibodies. The functionalized yarns and colloidal
gold-labeled antibodies are then employed in several configurations of
immunochromatographic assays in Chapter 5. Chapter 6 summarizes the findings of this
study and provides further recommendations for continuation of the research.
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Chapter 2
2 Literature Review
2.1 Immunology: A Brief Overview
2.1.1

The Immune System

The immune system defends the body from foreign invaders utilizing two
subsystems: innate immunity and acquired immunity. The body’s innate immunity is
derived from general mechanisms that prevent pathogens from entering or thriving in the
body. The protection offered by the skin as a physical barrier, the acidic pH of the
stomach and enzymes that breakdown foreign substances are examples of components
that make up the body’s innate immunity. Acquired immunity arises due to exposure to
specific stimuli.
Acquired immunity can be further broken down into cell-mediated immunity and
humoral immunity. Cell-mediated immunity begins with the recognition of an antigen by
T cells which leads to downstream cytotoxic activity, by cytotoxic T cells, and chemical
regulation of the body’s immune response, by helper T cells. The lymphokines, secreted
by helper T cells, and direct antigen interaction with cell membrane immunoglobulins
activates the B cells responsible for humoral immunity. Activated B cells differentiate
into memory B cells and plasma cells. Memory B cells are produced to quickly respond
to antigen presentation in the future. Plasma cells’ high-functioning and extensive rough
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endoplasmic reticulum enables this cell type to excrete large quantities of antibodies with
variable portions that are reactive with the antigen initializing the immune response.
Plasma cells are capable of secreting up to 2,000 antibody molecules per second. This
high antibody production rate may continue on a time scale of days to weeks [21, 22].
The antibodies produced by these plasma cells are a key component in the body’s defense
against foreign invaders.
2.1.2

Antibody Structure and Function

The term antibody is used to generalize five different classes of immunoglobulins,
which are glycoproteins that can be found in the cell membranes of B cells or in body
fluids. It is important to note that the physiological distribution, function, and structure of
immunoglobulins vary from class to class. Plasma immunoglobulins are dominated by
Immunoglobulin G (IgG), which composes 80% of immunoglobulins found in serum, at
about 12.5 mg/ml. The main immunoglobulin in saliva, nasal secretions, bronchial
secretions, tears, and colostrum is immunoglobulin A (IgA). It is primarily secreted in
mucosal membranes to defend against microorganisms, but can also be found in small
quantities in serum. Also found in serum, composing 10% of immunoglobulins there, is
the immunoglobulin M (IgM) class antibody. Allergic reactions are facilitated by
immunoglobulin E-antigen interactions. These physiological distributions and functions
are important to antibody employment in the development of immunoassays [21, 23]. The
structure of antibodies varies among the immunoglobulin classes and is related to
function and physiological location. For instance, IgM exists as a pentameric molecule
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and serum IgA can exists as a monomers, dimers, or trimers in secretions while secretory
IgA is a dimer that includes a secretory component [24]. A schematic of the basic
structure of an immunoglobulin G, or IgG, molecule is shown in Figure 1.

Figure 1. The protein ribbon structure of an IgG (2a) monoclonal antibody as determined
by X-ray diffraction. Shown here are the heavy chains (light green and light blue) and the
light chains (dark blue and dark green). Shown are the variable regions of the heavy and
light chains (VH and VL), the constant region of the light chain (CL) and heavy chains
(CH1 and CH2), the hinge, and the FAB and FC regions. Also visible is the antigen binding
sites (*) between the heavy and light chains. File downloaded from the protein data bank,
PDB ID: 1IGT [25, 26].
Immunoglobulin G molecules (150 kDa) are made up of two heavy chains (50 kDa)
each linked to a light chain (23 kDa) via disulfide bonds and non-covalent interactions
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[25, 27, 28]. The two Fab regions are composed of the variable regions of light chains
(VL) paired with variable regions of heavy chains (VH) and the constant regions of the
light chains (CL) paired with a part of the constant portion of the heavy chain (CH1).
Generally, the Fab region of an immunoglobulin is composed of 2 beta-sheets closely
packed and covalently linked by disulfide bridges in the constant region [28]. The pairing
of the VL and VC regions is where the specific antigen-antibody reactions occur. The
variable region can be further divided into the framework amino acid sequences and
hyper-variable regions, also referred to as complementarity-determining regions (CDRs).
The framework sequences provide structure to the protein and position the CDRs
properly to allow for antigen binding. The antigen binding sites are formed between the
heavy and light chain variable segments where the CDRs reside [23, 25, 27, 28]. The
pairing of the heavy chains constant portion (CH2a and CH2b) is referred to as the FC
region. The Fc region amino acid sequence contains the carboxyl group terminal end.
Antibodies can be produced that are either polyclonal, with the ability to recognize
several different epitopes, or monoclonal, recognizing only one epitope. Fixation and
denaturation of proteins usually does not destroy all epitopes that may be recognized by
polyclonal antibodies. The ability to recognize and react with several epitopes allows
polyclonal antibodies to be used on such processed samples as fixed tissue, for
immunohistochemical applications. In contrast, monoclonal antibodies are much more
sensitive to modifications. This may lead to non-reactive antigen binding moieties due to
epitope masking under different conditions [29]. The interactions between antibodies and
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their antigens need to be explored further to illustrate the functionality of antibodies, both
physiologically and for potential diagnostic applications.
2.1.2 Antibody-Antigen Interactions
All antibody-antigen complexes have a high affinity [25, 28]. These antigenantibody reactions are characteristically different, depending on the type of antigen,
whether the antigen is a protein, antibody, carbohydrate, or peptide. The protein antigenFab interface has high morphological complementarity, with hydrogen bonds, salt bridges
and van der Waals forces acting at the interface. These protein antigen-antibody
interactions have reported Ka values of 107-1010 M-1 [28]. Studies have shown that
hydrophobic interactions between antibodies and small molecules have had the highest
correlation with analyte binding. Other factors that influence the binding include
electrical and steric properties of analytes [30]. These antibody-antigen interactions
provide the basis for many diagnostic tests and tools in a variety of fields. Other than
diagnostic tests, antibodies have been used to study the physiological response to
biomaterials [31-37], as well as in therapeutic applications [38, 39].
Antibodies not only mediate the interaction of antigens with cells, they can also
neutralize the harmful effects of antigens directly via two separate mechanisms:
agglutination and masking key epitopes [21, 38, 40]. The agglutination resulting from
antibody-antigen interactions can be dramatic enough to precipitate soluble antigens out
of solution into a state where they are inactive [21, 40]. Of particular interest for this
study is the interaction between antibodies and influenza virus neuraminidase [3, 28, 40,
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41]. These antibody-antigen interactions inhibit neuraminidase and hemagglutinin
activity of the antigen [40].
Both monoclonal and polyclonal antibodies have been shown effective in
prophylactic and therapeutic use in vaccines. Antibodies’ antiviral properties arise from
the highly specific epitope binding mechanism. Antibodies can prevent virus entrance
into a cell by binding viral spikes, cell receptors or co-receptors, inducing cell or
endosomal membrane conformational changes, agglutination of virus, and inhibiting viral
product release [38-45].
The response by the immune system acts primarily to respond to the specific
stimuli encountered; however, it may also disclose information regarding the type of
invasive pathogen or infection. The antibodies produced respond as described above and
are found at elevated levels in tissues and body fluids, depending on the antibody type.
The elevated level of antibodies and biomolecules in clinical samples provides target
analytes to be probed and analyzed by biosensors to aid physicians in diagnosing the
pathogen or infective agent present. The physiological response, especially antibodies
and antigens, has been employed in the diagnosis of several conditions, including
influenza and human immunodeficiency virus.
2.2 Current Strategies for detecting conditions
Antibody-antigen interactions can be extremely useful in determining the presence of
a pathogen. Understanding these antibody-antigen interactions has allowed for the
development of immunoassays that are commonly used to detect a variety of conditions
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in every diagnostic testing setting: histology and clinical laboratories, point-of-care
settings, and in-home diagnostics. A sound understanding of immunoassay principles
allows for the assessment and comparison of current and prospective technologies for
advancement of diagnostics.
2.2.1

Immunoassay Principles

Immunoassays employ the inherent sensitivity, specificity, and binding affinities
of antibodies to respective antigens to detect the presence of antigen in a sample. Samples
typically tested include whole blood, plasma, serum, saliva, and respiratory fluids.
Immunoassay signals typically come from the accumulation of a labeled antibody at the
binding site for the antigen on a substrate. Typical antibody labels may be fluorescent
molecules, nano- or microparticles, or enzymes. These immunoassays can be employed
in industry, clinical or laboratory settings, doctor’s offices, or as over-the-counter tests.
Over-the-counter tests typically utilize the immunochromatography technique with
antibody labels that can be seen by the naked eye, such as gold nanoparticles or latex
beads [46, 47].
2.2.2

Immunohistochemistry

Histology is the study of tissue structure and function. Sections of tissues are
taken and stained with specialized stains to show different cells, structures, and
compounds present in the sample. Clinical histology can be taken from patients to aid in
the diagnosis of various conditions in patients. Histology has also been employed in the
field of bioengineering to examine the effects of medical devices, surgical techniques,

10

and other therapeutics administered to animal specimens. One histological tool that has
been found to be particularly useful is immunohistochemical staining. Immunostaining of
cells or cellular structures can be performed with antibodies labeled with an enzyme, such
as horseradish peroxidase (HRP), or fluorescent labels, that will reveal antibody locations
after chemical reaction or excitation by specific wavelengths, respectively [36, 37, 4852]. Traditionally histology is used in hospital or clinical laboratory settings to aid in the
diagnosis of various conditions. More recently it has been found useful in the analysis of
the physiological response to implanted biomaterials [31-37]. This principle, using the
specific and sensitive reactions of antibodies and antigens, can be adapted and used to
detect antibody presence on nanofiber yarns, as well as specific reactivity of immobilized
antibody on nanofiber yarns. The same interactions can be applied to some clinical
laboratory diagnostic tests.
2.2.3

Laboratory Analysis

There are several diagnostic tests methodologies that provide excellent sensitivity,
such as enzyme immunoassays (EIAs) and viral cell cultures currently used for the
diagnosis of HIV and influenza, respectively. Other methods include polymerase chain
reaction (PCR) and enzyme-linked immunosorbent assay (ELISA). While these
techniques offer exceptional sensitivities, they do require technical knowledge and
expertise. Also required for both of these methods is expensive equipment that may not
be available at the point-of-care, and will certainly not be available for patients’ selfdiagnosis [11, 13, 53-56]. To illustrate the complexities that can be associated with these
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methods a brief description of viral cell culture for influenza diagnosis and enzyme
immunoassays for HIV follows.
2.2.3.1 Viral Cell Culture
There are various methods and tools available to clinicians to aid in the diagnosis of
influenza. Conventionally, viral cell cultures are performed and considered the “gold
standard” for virus diagnosis [5-8]. Specimens used in this method include
Nasopharyngeal (NP) swabs, throat swab, NP or bronchial washes, nasal or endotracheal
aspirate, and sputum [7]. A general procedure for collecting and analyzing specimens by
viral cell culture is briefly described as follows: These specimens are collected with
swabs made of Dacron or polyester, and then placed in special medium for transport to
the laboratory. The viral transport medium (VTM) generally contains antibiotics
necessary eliminate potential microbial contamination, buffer solution with pH indicator,
and a protein source. The tube containing VTM and the sample collection swab is mixed
thoroughly, and the swab is then removed. The VTM with sample is centrifuged to a
pellet, containing cells, bacteria and other large particles, and supernatant. Due to their
size, viruses are not spun down into the pellet. The virus-containing supernatant is
collected and added to a cell culture or used to inoculate via adsorption inoculation. For
adsorption inoculation, cell culture medium is discarded and the viral supernatant, or
inoculation medium, is applied to the cell monolayer and incubated at 37°C for various
time periods depending on the specimen type and viral infection of interest. The cells
cultured with the inoculation medium are observed using a light microscope for
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proliferation of the suspected virus. Expertise is required to recognize the effects of virus
on the cell monolayer, especially for early or subtle changes. Changes in the cell culture
due to viral infection, or cytopathic effects, can be seen for most viruses around 5-10
days post-inoculation. However, this time period varies depending on the virus type [7].
This time period for diagnosis can be reduced using more advanced methods of viral
isolation. Viral inoculation can be enhanced by centrifugation-enhanced techniques. The
processed sample is deposited directly onto a small coverslip that can fit into
centrifugation tubes, after the VTM has been removed. Low centrifugal force is applied
the vial and fresh culture medium is then added and the sample is incubated at 37°C. The
coverslip with the clinical sample is subsequently stained with horseradish peroxidase
(HRP) or fluorescently labeled antibodies. Examination with light microscopy (HRPlabeled antibodies) or fluorescent microscopy (fluorescently labeled antibodies), can
reveal viral infection as early as 48 hours post-inoculation [5-7]. However, this rapid
virus isolation technique increases diagnosis costs from equipment and reagents.
Despite the challenges presented by the turn-around time by the viral cell culture
methods, samples must be transported to clinical laboratories under controlled conditions,
special equipment and reagents are required in the clinical laboratory, and skilled
technicians must perform the experiments. All these factors add to the cost and
complexity of the diagnosis.
Antiviral regimens started after the first 48 hours have also been shown to reduce
symptom and complication severity [2-4, 57]. This would help relieve some of the
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financial burden of the influenza virus, which is especially important to those without
sufficient resources and those without health insurance coverage. Those hospitalized by
influenza could decrease their length of stay reducing the cost associated with the virus.
Therefore, decreasing the turn-around time for patient diagnosis is important.
2.2.3.2 Enzyme Immunoassay
The current “gold standard” for HIV testing is an HIV enzyme immunoassay
(EIA) for detection of HIV-1 and HIV-2 antibody presence with a western blot or
immunofluorescence assay (IFA) to confirm the presence of HIV-1 antibody [14]. These
tests can be performed with plasma or serum analytes. False negatives often result
because although there is HIV infection present, the EIA may be non-reactive from 8-12
weeks post-infection. While these tests are sensitive, there is the need to send samples to
a lab, increasing costs and turn-around time required to diagnose a patient [14, 58].
Enzyme immunoassays can also be performed on oral fluid specimens, which can be
more convenient for collection. However, oral fluid samples for EIA still require sample
transportation to a laboratory and are more expensive than traditional EIA techniques.
The turn-around time for these samples is reduced to 3-5 business days [14]. Another
advantage oral fluid specimens is that collection less invasive and hazardous to
handle[58]. Enzyme immunoassays have proven effective in detecting the presence of
HIV; however, this methodology is too complex to be used outside of clinical laboratory
settings and, like viral cell culture, involves a long turn-around time.
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2.2.4

Clinical Laboratory Improvement Amendments (CLIA)

Simplification of diagnostic testing methods allows for an increased availability
of the diagnostic tests to patients with a shorter turn-around time. However, this
simplification and increased availability must not detract from the reliability of the
diagnoses. The Clinical Laboratory Improvement Amendments (CLIA) law specified that
the complexity of tests should determine laboratory requirements. Diagnostic tests and
assays are rated on their complexity by the FDA based on knowledge, training and
experience required, reagent and material preparation, characteristics of operational steps,
calibration, quality control, and proficiency testing materials, test system troubleshooting
and maintenance, interpretation and judgment. The simplest diagnostic tests require little
scientific or technical knowledge, where all required information can be learned on-site.
Minimal training and experience should be required to conduct and analyze the results of
the test. Reagents used in the tests should be stable and reliable, requiring no special
handling, preparation, or storage conditions. The diagnostic test should also be
operationally simple, preferably with automated steps. All calibration, quality control,
and proficiency testing materials should be stable and readily available. Troubleshooting
of the test system should be either automatic or self-correcting, or clearly described
without experienced judgment required. Maintenance should also be provided by the
manufacturer, rarely needed, or simple for the user. Importantly, there should be little
room for judgment or interpretation error for analysis or resolution of problems [59].
Diagnostic tests that are CLIA waived, and therefore exempt from regulation, should be
simple and accurate enough to ensure high probability of correct results [60].
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There has recently been a shift toward the development of cheaper, CLIA-waived
point-of-care diagnostic tools [8, 56]. These point-of-care diagnostics do not require the
need for specialized and expensive equipment or extensively trained staff. The samples
do not need to be specially handled and stored for transportation from the doctor’s office
to a clinical laboratory for analysis. The samples can also be analyzed by those on staff at
the point-of-care, rather than specially trained clinical laboratory technicians. All these
factors allow reduce the time and cost for diagnosis, enabling early treatment [5-9, 56].
The early treatment and increased availability for these CLIA-waived test is especially
important for conditions such as influenza and HIV.
2.2.4.1 CLIA-waived Diagnostic Tests
The development of CLIA-waived influenza tests has been of particular interest
due to the improvement in healthcare associated with earlier diagnosis. Rapid diagnostic
influenza tests are listed with their sensitivities and specificities in Table 1.
Table 1. CLIA-waived RIDTs currently on the market along with specimens approved for
CLIA-waived use along with the time to run the diagnostic test.
CLIA-waived RIDTs
BD Veritor System for Rapid
Detection of Flu A+B
BinaxNOW® Influenza A&B
QuickVue® Influenza Test
QuickVue® Influenza A+B Test
SAS™ FluAlert A
SAS™ FluAlert B

Approved Specimens
NP swab/nasal swab
NP swab; Nasal
wash/aspirate/swab
nasal wash/aspirate/swab
NP swab; Nasal
wash/aspirate/swab
Nasal wash/aspirate
Nasal wash/aspirate
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Time
10 minutes
15 minutes
10 minutes
10 minutes
15 minutes
15 minutes

It has been shown that nasopharyngeal samples have shown the highest sensitivity
for sample collection in lateral-flow RIDTs, due to the availability of the antigen [11, 6165]. While RIDTs can provide a convenient method to detect the presence of influenza
antigens, it has been shown that some RIDTs offer lower sensitivity compared to the
“gold standard” for influenza diagnostic tests [11, 61, 66]. There are RIDTs available that
allow for detection of analyte in the nanogram range [8, 62]. However, when compared to
RT-PCR tests, commercially available RIDTs result in decreased clinical sensitivity (7090% in children and <40-60% in adults). Thus, it is recommended to confirm negative
results via RT-PCR or viral cell culture [65]. Another concern is the variability of
sensitivities that have been found in studies comparing RIDTs to RT-PCR. For the same
commercially available RIDT, studies from different investigators have shown values for
the sensitivity from 20% [11, 12] to 53.3% [10, 11]. Not only are these commercially
available RIDTs lacking in sensitivity, with some shown to be as little as 9.7% sensitive
[13], there is also variability and large amounts of inconsistencies with different users
[11].
Some RIDTs are categorized as CLIA-waived tests, which facilitate the ease of
use as point-of-care diagnostics. However, RIDTs are not available for over-the-counter
testing, largely due to the discomfort associated with collecting the nasopharyngeal
samples with higher antigen availability. Thus, there exists a need for the development of
a highly sensitive RIDT that will cause less discomfort for patients and could possibly be
used as an in-home diagnostic tool after an affordable over-the-counter purchase.
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The benefits of earlier diagnosis of HIV have also drawn attention for CLIAwaived tests for this virus. CDC recommendations for HIV testing have been put forth
and altered over the years. These recommendations are based on individuals’ risk of
contracting the virus, with higher risk patients testing more frequently than lower risk
individuals. The latest CDC recommendation, from 2006, is that low risk individuals get
tested once for HIV, while those at high risk receive annual testing [14, 18, 67, 68]. A
study by Lucas, et al, showed testing for HIV more frequently and earlier administration
of HAART is actually more effective in terms of dollars per quality-adjusted life-years
(QALY). This study recommended HIV testing every three months for those at high risk
of contracting HIV, giving an incremental cost effectiveness of $45,074/QALY [67].
It has been shown and is widely accepted by clinicians that early diagnosis of HIV
decreases the chance for transmission of the disease and allows for administering highly
active antiretroviral treatment, or HAART, earlier increasing quality of life, survival rates
and patient longevity [14-17]. Testing for HIV more frequently reduces the risk for
transmission of the disease and allows for early antiretroviral treatment, improving
patient outcomes [14-16].
The FDA has approved 6 rapid HIV diagnostic tests that are commercially
available in the United States: OraQuick® Rapid HIV-1/2 Antibody Test (OraSure
Technologies, Inc.), Reveal G3 Rapid HIV-1 Antibody Test (MedMira, Inc.), Uni-Gold
Recombigen HIV Test (Trinity BioTech), Multispot HIV-1/HIV-2 Rapid Test (Bio-Rad
Laboratories), Clearview HIV 1 / 2 Stat PaK and Clearview Complete HIV 1 / 2
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(Inverness Medical Professional Diagnostics). Each CLIA-waived HIV test requires
whole blood, with the exception of the OraQuick® tests, which can also use saliva
samples.
These rapid tests require confirmation for reactive (preliminary positive) results
and repeat testing for invalid results. A major advantage of these rapid tests is that they
can be used in point-of-care settings and results can be obtained within 10-30 minutes.
This is especially important in low resource settings such as correctional facilities and
low-income areas [69-71]. While these rapid tests incur higher material cost than
traditional HIV testing, the cost per HIV-infected patient test result was lower, as
confirmatory EIA and western blots are not required for non-reactive rapid test results
[14, 58].
In 2012, the first over-the-counter HIV test for at-home use gained pre-market
approval from the FDA. The OraQuick® In-Home HIV Test was derived from the
OraQuick® Advance HIV-1/2 Antibody Test. Phase III clinical studies of the OraQuick®
In-Home HIV Test yielded a sensitivity of 91.7% [72]. The OraQuick® In-Home HIV
costs $39.99 per test kit. There exists a need to reduce the cost of these in-home tests, to
increase availability to patients with minimal resources. This is especially important
considering 75% of persons infected with HIV in the United States were at or below the
poverty level [72].
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The most popular platform for CLIA-waived rapid diagnostic tests has proven to
be immunochromatography. This is partially due to the simplicity by which high signal
intensity and clarity can be achieved as well as financial considerations.
2.2.5

Immunochromatographic Assays

Immunochromatographic assays are available as over-the-counter tests for several
conditions, such as pregnancy, drugs of abuse, HIV, and other conditions [46, 47]. The
antibody labels used in this test, commonly gold nanoparticles are typically visible with
the naked eye. This eliminates the need for expensive equipment required to provide the
user with an output [46, 47].
The immunochromatography technique allows for visible detection of an antigen
in a sample by the naked eye, eliminating the need for expensive equipment availability
to the end-user. An antibody is typically optically labeled with a colored nanoparticle.
Oftentimes, the labels of choice are gold nanoparticles of various sizes, typically between
5-50 nm [51, 73-87]. Gold nanoparticles in this size range allow for a much higher
specific surface area compared to those of the same optical density in the 100-200 nm
range or larger [47]. This allows more analyte-detecting proteins to be immobilized to the
surface, increasing the sensitivity of the immunoassay [47]. Compared to larger
nanoparticles, there is less variability in the signal brightness with concentration of
analyte when using smaller nanoparticles [47]. The small size of the gold nanoparticle
label does not interfere with the flow and migration of the labeled antibody through the
membrane to the reactive zone [54, 88]. The excellent optical properties of gold
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nanoparticles allow for increased sensitivity of the immunochromatographic assays,
revealing presence of analyte in the ng/ml range [54, 73, 88]. Pregnancy tests are
immunoassays that generally detect the presence of human chorionic gonadotropin (hCG)
in urine samples. An independent evaluation of over-the-counter pregnancy tests found
sensitivities in the 25-100 mIU/ml, or approximately 2-7 µg/ml [89, 90]. Other
immunoassays can show higher sensitivity. Lateral-flow rapid influenza diagnostic tests
have shown sensitivity in the ng/ml range.
While expensive equipment is not required and less skill is involved in
administering lateral flow immunoassays, issues with sensitivity have become apparent.
Rapid influenza diagnostic tests (RIDTs) have been shown to provide sensitivities less
than 40-60% in adults [65]. This may lead to the need for confirmatory testing to be
carried out, further increasing the cost of the diagnosis and treatment of the patient.
Lateral-flow diagnostic tests are not limited to the healthcare setting. They have
been employed in a variety of fields other than healthcare. They have been shown
effective in forensics [88, 91], pathogen detection in feed [73, 74, 80, 88, 92-96] and
plants [55, 73, 88], as well as for ecological samples such as soil and water [73, 75, 88,
97]. These lateral-flow diagnostic tests can be used at the point-of-care or industry setting
as well as for in-home diagnoses.
2.2.6

At-Home Diagnostic Tests

The most popular configuration for these tests is the lateral flow immunoassay
(LFIA) tests. Generally these tests have several components: a sample pad to which
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specimen is added, a conjugate pad with labeled antibodies specific to the antigen of
interest and control antibody or molecule immobilized in the test region, a membrane
testing zone with a test antibody specific to the analyte and a control antibody specific to
the antibody labeled in the conjugate pad, and a reservoir that provides extra wicking
forces and retention of labeled antibody that does not react with the test or control stripes.
All these components are attached on a plastic backing. The reservoir pad is made of
absorbent material that enhances wicking along the membrane to ensure all possible
conjugates reach the reaction zone and reduces background noise. The testing membrane
is typically composed of nitrocellulose. The conjugate pad is often a borosilicate glass
fiber pad with low-retention characteristics allowing it to release dried gold nanoparticlelabeled antibody to the nitrocellulose membrane. The sample pad is usually an absorbent
material, such as cellulose. A schematic of the general LFIA diagnostic tests is shown in
Figure 2. The cost of these LFIA diagnostic tests can be high. The OraQuick® In-Home
HIV costs $39.99 per test kit. There exists a need to reduce the cost of these in-home
tests, to increase availability to patients with minimal resources. This is especially
important considering 75% of persons infected with HIV in the United States were at or
below the poverty level [72].
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Figure 2. A schematic representative of typical lateral-flow immunoassay devices. Shown
here are the components (a) the sample pad, conjugate pad with gold-antibody
conjugates, test lines, and control line on the nitrocellulose membrane, and the absorbent
pad, all on the plastic backing. Also shown is the procedure and possible results (b) for
gold-labeled antibodies recognizing antigens as well as the control line antibody (goat
anti-mouse).This schematic was reproduced from a study by Choo Yee Yu et al [79].
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Chapter 3
3 Specific Aims and Significance
3.1 Significance
Currently, immunochromatography principles are utilized in diagnostic tools for
clinical laboratory, point-of-care, and in-home testing. The diagnostic tools have proven
valuable in decreasing the diagnosis turn-around time for patients when compared to
conventional methods, such as viral cell culture [5-7]. In many cases, such as lateral flow
immunoassays for diagnosis of influenza, this is largely due to the ability of the tests to
be administered at the point-of-care. Other diagnostic tests, such as pregnancy tests, can
be purchased over-the-counter for an at home diagnosis. The simplicity of the lateral flow
immunoassay platform allows them to be administered with little training and with little
chance of error. However, these diagnostic tools do have limitations effecting their
efficacy and availability to the full market potential, most notably, cost and sensitivity.
Rapid influenza diagnostic tests (RIDTs) have been shown to have sensitivities <40-60%
in adults [65]. This sensitivity may be increased by developing a nanofiber-based
immunoassay platform. The high specific surface area of nanofiber yarns and different
detection antibody immobilization techniques may increase the sensitivity of the
diagnostic tests. Another concern for the RIDTs is the availability to the patient. Sample
collection and processing does not allow for these tests to be purchased over-the-counter
for in-home diagnoses. Decreasing the discomfort and complexity of these tests may
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increase the availability of diagnostic testing and quality of healthcare to patients that are
unable to make it to a point-of-care diagnostic testing facility. The manufacturability of
these diagnostic tests can also be increased. Reducing the components utilized in the
manufacturing of these tests can reduce cost and increase the manufacturability. A fiberbased immunoassay system may be incorporated in multiple configurations, which may
not necessitate individual housing and packaging of tests.
3.2 Specific Aims
3.2.1

Development of a Fiber-based Immunoassay System

This study aims to incorporate immunoassay technology that is currently used for
diagnostic tests into a fiber-based system to: increase the sensitivity, decrease the number
of components in manufacturing, thereby reducing cost, and facilitate simpler and more
comfortable sample collection to simplify the procedure. Several goals need to be
accomplished for successful development, verification, and validation of this system.
3.2.1.1 Preparation of Immunoassay Yarns
Electrospun polymer nanofiber yarns were prepared and characterized, yielding a
high specific surface area. The several different compositions of yarn will be examined
for feasibility of employment into an immunoassay system. The ability to bind antibodies
using a covalent cross-linker will be determined as well as the retention of antibody
activity after yarn functionalization. The blocking procedure is also verified to ensure no
loss of functionality occurs.
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3.2.1.2 Preparation of Colloidal-Gold Labeled Antibodies
Colloidal-gold labeled antibodies will be prepared to detect analyte in solution
and provide an optical signal as an output on the surface of the nanofiber yarns. Complete
adsorption of protein to the gold nanoparticle surface will be verified via flocculation
tests.
3.2.1.3 Fiber-based Immunoassay Performance
After the components to be employed in the immunoassay system have been verified,
the viability of their employment will be validated using model antibody-analyte systems.
Performance will be assessed by the signal provided for positive and negative analyte
samples, based on clarity and intensity.
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Chapter 4
4 Preparation of Nanofiber Yarns
4.1 Introduction
Antibodies have been shown to physically adsorb against many substrates, while
retaining their specific activity towards an antigen. Many lateral flow immunoassay
membrane preparation techniques employed in industry and academia rely on the
electrostatic interactions of the antibodies to the nitrocellulose membranes [75, 76, 80,
98]. Oftentimes, the antibody is dispersed on the nitrocellulose membrane by a jet
dispenser in a low-volume state. This prevents antibody spreading by capillary forces
along the membrane, leaving sharp and distinct physically adsorbed antibody stripes.
This method of antibody immobilization relies on electrostatic interactions. Other
materials that are used as the test membrane rely on hydrophobic interactions. The
physical adsorption of antibody to a surface can cause the antibody to lose some activity
due to orientation of the antibody. It has been shown that 90% of physically adsorbed
antibody may be in an orientation that causes complete loss of activity due to steric
hindrance of the antigen binding site [53, 99, 100]. Additionally, covalently cross-linked
antibody can be immobilized with higher efficiency than physically adsorbed antibody.
Thus, to immobilize antibodies to our nanofiber yarn, we will utilize a photo-reactive
covalent cross-linker.
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Chemical modification of antibodies has been shown to decrease or completely
inhibit antibody activity by masking the epitopes for antigen binding. This is especially of
concern for monoclonal antibodies, as they are only able to recognize one epitope [29].
Thus, attachment of antibodies to biosensor substrates is often accomplished by physical
adsorption. The antibody-substrate hydrophobic interactions can be undefined and lack
stability which can cause activity loss and low binding efficiency of the antibody to the
substrate [101-106]. Covalent attachment of antibodies to the substrate can define the
region of the antibody that is bound to the surface of the biosensor, ensuring activity and
availability of the antigen binding region [101-104, 106]. Covalent antibody attachment
to a substrate also has higher reproducibility compared to physical adsorption methods
[107]. Heterobifunctional photo-reactive cross-linkers have been shown to be effective in
immobilizing biomolecules on polymeric substrates while retaining antigen binding
availability and activity [101-106]. One moiety of the photo-reactive cross-linker is
activated by UV light to react with the substrate, while the other specifically binds the
biomolecule of interest to the photo-reactive cross-linker [103, 106]. Common photoreactive cross-linkers that have been studied are ketyl-reactive or nitrene/carbene-reactive
cross-linkers. Diazirine compounds are carbene-reactive photo-reactive cross-linkers
[101, 103, 106, 108, 109]. The diazirine moiety is activated by long-wave (330-370 nm)
UV irradiation to form a carbene intermediate, which can then insert via addition
reactions with carbon-carbon double bonds, reaction with activated carbon-hydrogen or
nitrogen-hydrogen bond, oxygen-hydrogen bonds, or sulfur-hydrogen bonds. This allows
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the photo-reactive cross-linker to form stable conjugates with the substrate, amino acid
side chains or peptide backbones [101, 103, 106, 108, 109]
There are several methods that have been shown to determine antibody activity
quantitatively [110], semi-quantitatively [111], and qualitatively [107]. Fluorescent
immunohistochemical staining was chosen to verify antibody activity retention after
cross-linking the antibody to the nanofiber yarn.
4.2 Materials and Methods
4.2.1

Materials

Electrospun nanofiber yarns were prepared by our collaborators with
compositions of poly(vinylidene fluoride)/poly(ethylene oxide) (PVDF/PEO), PVDF,
polyacrylonitrile (PAN), cellulose acetate/polyacrylonitrile (CA/PAN), cellulose
acetate/poly(methyl methacrylate) (CA/PMMA), and poly(methyl
methacrylate/poly(ethylene oxide) (CA/PMMA/PEO). Rabbit anti-bovine IgG, FITClabeled goat anti-rabbit IgG, bovine anti-mouse IgG, biotinylated bovine anti-mouse IgG,
mouse anti-FITC IgG, biotinylated mouse anti-FITC IgG, and goat anti-mouse IgG
antibodies were purchased from Sigma-Aldrich Corporation. Streptavidin was purchased
from Rockland Immunochemicals, Inc. The photo-reactive sulfo-NHS-LC-diazirine
cross-linker was purchased from Thermo Scientific, Incorporated. The fluorescent dyes
used for labeling were Alexa Fluor® 350, 488, and 594 were purchased from Life
Technologies Corporation (InvitrogenTM). Fluorescein Isothiocyanate (FITC) was
purchased from Alfa Aesar. Blocking solutions of ethanolamine (Acros Organics), bovine
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serum albumin (BSA) and Tween 20 (Acros Organics) were made in 10 mM phosphate
buffered saline buffer purchased from Fischer Scientific. The Spectroline® Model XX15A long wave ultraviolet light lamp (365 nm) was purchased from Spectronics
Corporation.
4.2.2

Yarn Preparation

Nanofiber yarns were prepared by the electrospinning method report previously
by our collaborators: Chen-Chih Tsai, et al [112]. To determine the porosity of the yarn a
tributyl phosphate (TBP) droplet of known volume (Vd) was added to a yarn of lesser
volume (Vy), such that Vd > Vy. The radius of the yarn (Ry) was measured by optical
microscopy (Olympus BX-51) and used to calculate the volume of the yarn (Vy) of a
known length (L) with the following equation:

L. After complete wetting of the

yarn by the TBP droplet, the yarn was placed on a scale (Sartorious, BP-221S) for mass
measurement. The low vapor pressure of TBP (0.00012 mm Hg at 25°C) prevents
evaporation of the TBP throughout procedure and measurements. The porosity of the
yarn was then calculated as
completely wetted yarn,
g/cm3), and

, where
is the mass of the dry yarn,

is the mass of the
is the density of TBP (0.979

is the volume of the yarn. The average porosity of three CA/PMMA/PEO

yarns was found to be

The methodology to determine the yarn

permeability described in a paper by Callegari, et al was utilized here [113]. The
permeability of the yarn was determined to be
arguments suggest that the interfiber distance is measured as
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m2. The scaling
[114].

4.2.3

Yarn Functionalization

The efficiency of antibody immobilization on various nanofiber yarn compositions is
another important parameter to consider when selecting a material for the immunoassay
yarn. To this end, antibodies labeled with fluorescent dyes were covalently attached to
the fiber surface of the various compositions: PVDF, PVDF/PEO, PAN, CA/PAN,
CA/PMMA, and CA/PMMA/PEO yarns.
The antibodies to be immobilized on these nanofiber yarns (goat anti-rabbit IgG and
rabbit anti-bovine IgG) were purified from sodium azide by centrifugal filtration. The
pure antibodies were then re-suspended in 1X PBS (pH 7.4). The UV-sensitive sulfoNHS-LC-diazirine cross-linker was dissolved in 1X PBS at a concentration of 1 mg/ml.
The goat anti-rabbit IgG and rabbit anti-bovine IgG antibodies were added to separate
aliquots of the sulfo-NHS-LC-diazirine solution and incubated with shaking at room
temperature for 1 hour to allow for conjugation of the UV-sensitive cross-linker to the
antibodies. The antibody-cross-linker conjugates were then purified from excess sulfoNHS-LC-diazirine by centrifugal filtration and re-suspended in 1X PBS (pH 7.4).
To prevent capillary pressure wicking reactive antibodies towards each other, a 2 µl
droplet of 10 mM PBS was added to the center of the CA/PMMA/PEO nanofiber yarn. A
2 µl droplet of goat anti-rabbit IgG was added 1 cm from one end of the yarn and a 2 µl
droplet of rabbit anti-bovine IgG was added to 1 cm from the other end of the yarn
immediately following the addition of the PBS droplet. A 2 µl droplet of 10 mM PBS
was then added to each end of the yarn. Slits were cut in a UV-protective mask to ensure
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that narrow and distinct antibody stripes were immobilized on the yarn. The masked
CA/PMMA/PEO nanofiber yarn loaded with antibody-cross-linker conjugates was
exposed to UV light at 365 nm for 20 minutes. This method was proven effective by
immobilizing fluorescently labeling reactive antibodies with Alexa Fluor® 488 and
Alexa Fluor® 594, respectively, on a CA/PMMA/PEO nanofiber yarn and imaging with
fluorescent microscopy. Independent and distinct antibody stripes would show
fluorescence from the Alexa Fluor® 488 dye only at the site of the 488 labeled
antibodies, and no 488 fluorescence at the location of the Alexa Fluor® 594 labeled
antibody, and vice-versa.
The yarn was then dried by wicking the fluid away simultaneously at each end with a
tissue. The yarn was then washed by adding a droplet of PBS to the center of the yarn and
wicking the fluid away simultaneously at both ends. The washing of the yarn by wicking
from the center to both ends of the yarn simultaneously allows the excess antibody to be
removed from the yarn without reacting with the other antibody immobilized on the yarn.
The antibody-conjugated CA/PMMA/PEO yarn was then blocked in a 5% (w/v) bovine
serum albumin (BSA) solution at 37°C for 3 hours. The optimum yarn blocking solution
was determined by blocking the CA/PMMA/PEO nanofiber yarns with 1%
Ethanolamine, 1% Ethanolamine with 0.05% Tween 20, 5% (w/v) BSA, and 5% (w/v)
BSA with 0.05% Tween 20. These yarns were then coated with platinum and examined
by scanning electron microscopy (Hitachi S4800).
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4.2.4

Antibody Activity

For the development of an immunoassay system, it is important that the detection
biomolecules or antibodies in this case, are capable of recognizing the target analyte, also
antibodies for this system. Because chemical modification can potentially mask the
binding moieties of antibodies, a system without chemical modification was used to
validate antibody-antibody interactions.
The streptavidin-biotin reaction has been shown to have extremely high affinity
capable of being applied in biosensor applications [1, 6, 115-117]. From this knowledge,
it can be concluded that immobilization of streptavidin on the nanofiber surface followed
by subsequent streptavidin-biotin reaction with a biotinylated antibody without losing
loading efficiency of antibody on the nanofiber yarn. This reaction may, in fact, increase
the loading efficiency of antibody on the nanofiber yarn and increase the sensitivity of the
immunoassay system. This system will also eliminate the need for chemical modification
of the antibody which could potentially result in loss or complete elimination of antibody
activity. In order to confirm activity of the antibody after cross-linking streptavidin to the
nanofiber substrate then adding biotinylated antibody to react with the immobilized
streptavidin and followed by the addition of antigen to the yarn,
immunohistofluorescence staining was performed.
Streptavidin was cross-linked to the yarn with the heterobifunctional photoreactive sulfo-NHS-LC-diazirine cross-linker using the same method as described
previously for antibody attachment to the nanofiber yarn. Streptavidin (1 mg/ml) was
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incubated with sulfo-NHS-LC-diazirine cross-linker in 10 mM PBS at room temperature
for 1 hour with shaking at room temperature. The streptavidin-cross-linker was then
purified from excess cross-linker by membrane centrifugation. Small droplets of
streptavidin were then added to the yarn at two different locations, where the test and
control antibodies will be attached. A mask was made by cutting slits in aluminum foil to
protect the areas of the yarn where streptavidin is not wanted to be immobilized. This
mask will allow for the covalent attachment of two sharp and distinct stripes of
streptavidin for reaction with biotinylated antibody. Non-covalently attached streptavidin
was then washed away from the yarn by wicking PBS buffer along the entire length of
the yarn.
Biotinylated bovine anti-mouse IgG and mouse anti-FITC IgG were labeled with
Alexa Fluor® 488 and 594, respectively. A 2 µl droplet of PBS was added in the middle
of the yarn, between the two streptavidin stripes immediately before the simultaneous
addition of the antibody droplets. This was necessary to prevent wicking of the antibodies
along the length of the yarn to the other antibody stripe. Had this occurred, the bovine
anti-mouse IgG would recognize the mouse anti-FTIC IgG at both locations and
fluorescence from both would be evident. After addition of the antibodies to their
respective streptavidin stripes, the yarn was incubated for 30 minutes at room
temperature to facilitate the streptavidin-biotin reactions. To remove the un-reacted
antibody from the yarn, the yarns were washed by wicking of a PBS droplet from the
center of the yarn to both ends. This washing method was employed to prevent wicking
of the excess antibodies to the other antibody stripe, where the bovine anti-mouse IgG
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would recognize and bind to the mouse anti-FITC IgG, resulting in fluorescence from the
488 and 594 dyes at both locations. The yarns were then blocked by immersion in 15 ml
of 1% ethanolamine blocking solution and incubated for 3 hours with shaking at 37°C.
Bovine serum albumin (BSA) was labeled with FITC by adding FITC to BSA in
0.1 M sodium bicarbonate buffer and incubating at room temperature with shaking for 2
hours. Excess FITC was purified from the FITC-labeled BSA by membrane
centrifugation and re-suspending the FITC-labeled BSA in PBS, and then dialyses against
PBS. Mouse anti-FITC was labeled with Alexa Fluor® 350.
4.3 Results and Discussion
4.3.1

Yarn Functionalization

All yarn compositions allowed for antibody immobilization on the nanofiber
surface using the photo-reactive cross-linker. The method for covalently immobilizing
antibodies to the CA/PMMA/PEO nanofiber yarns and preventing reactive antibodies
from interacting with each other was proven effective. Typical results are shown below in
Figure 3. Green fluorescence from Alexa Fluor® 488 can be seen only at the bovine antimouse stripe, while red fluorescence from Alexa Fluor® 594 can be seen only at the
mouse anti-FITC stripe.
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Figure 3. Typical results of antibody immobilization on yarn via sulfo-NHS-LC-diazirine
followed by washing and blocking steps. Alexa Fluor® 594 labeled mouse anti-FITC
(left) and Alexa Fluor® 488 labeled bovine anti-mouse IgG (right) are shown with
fluorescent microscopy (bottom) and as visible by the naked eye after UV excitation
(top).
The droplet of buffer in the middle of the yarn prevented capillary forces that
would have wicked the antibodies toward one another. Had this happened the antibodies
would have reacted and potentially lost reactivity and been unable to recognize analyte in
the final immunoassay system. Washing by wicking the droplet away from the center
allowed the capillary pressure to wash the antibody from each stripe away from the other
stripe, preventing antibody reaction throughout this step as well.
4.3.1.1 Determination of Optimal Blocking Method
The SEM images used for analysis of the different blocking solutions can be seen
below in Figure 4. Nanoporous structures can be seen in the 5% BSA with 0.05% Tween
20 and 1% Ethanolamine with 0.05% Tween 20 blocking solutions. Nanoporous
structures can also be seen in the CA/PMMA/PEO yarn that has had the PEO washed out
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in MilliQ water. Crystal structures can be seen on the surface of the CA/PMMA/PEO
nanofibers that have been blocked with ethanolamine blocking solutions.

Figure 4. The surface topography of the CA/PMMA/PEO yarns after blocking in 1%
Ethanolamine, 1% Ethanolamine with 0.05% Tween 20, 5% BSA, and 5% BSA with
0.05% Tween 20, in order from left to right.
The SEM investigation on the effect different blocking solutions have on the
surface topography of the nanofibers was quite interesting. The blocking solution chosen
for the remainder of the study was the 5% BSA solution without the presence of Tween
20. The ethanolamine blocking solutions affected the surface topography, and could
ultimately have some influence in the wicking properties of the final immunoassay yarn.
The blocking solutions that contained Tween 20 also showed changes in surface
topography compared to the unmodified yarns. Some nanoporous pitting is evident on the
surface of the 1% ethanolamine with 0.05% Tween 20 blocked yarn and on the 5% BSA
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with 0.05% Tween 20 blocked yarns, but not on the 1% ethanolamine and 5% BSA
blocked yarns. Thus, 5% BSA without any Tween 20 is the best blocking solution to use
for this application. It allows the fibers to keep the surface topography of the unmodified
CA/PMMA/PEO yarns. This will prevent any decrease in wicking of nanoparticle
conjugates in the final immunoassay system due to hindrance by rough surfaces of the
yarn or entrapment in holes and pits on the surface of the fibers. Also evident from the
SEM images of different CA/PMMA/PEO yarns was that washing the yarns in water
overnight resulted in pitting and porous structures in the surface topography of the fibers,
due to the washing out of PEO from the yarn structure.
4.3.2

Antibody Activity

There is fluorescent signal apparent at the site of streptavidin immobilization with
the photo-reactive cross-linker, shown in Figure 5. After the incubation of streptavidin
functionalized yarns with biotinylated bovine anti-mouse IgG and biotinylated mouse
anti-FITC IgG antibodies, fluorescent signal was apparent from the Alexa Fluor® 350
and Alexa Fluor® 594 dyes, respectively. Mouse anti-FITC IgG labeled with Alexa
Fluor® 594 was then added to the yarn with the streptavidin-biotin-bovine anti-mouse
IgG functionalization and a control yarn. Fluorescent signal from the red dye was only
visible on the streptavidin-biotin-bovine anti-mouse IgG functionalized yarn. The
fluorescent signal ratio of the test yarn to the control yarn was 3.3:1. The yarn
functionalized with streptavidin-biotin-mouse anti-FITC and the control yarns were
incubated with FITC labeled BSA. After washing of the yarns the functionalized yarn
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showed higher fluorescent signal from the FITC label than the control yarn, with a
fluorescence ratio of 1.7:1. Immunohistofluorescence images are shown below in Figure
6.
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Figure 5. Shown here are typical results seen from immobilization of fluorescently
labeled streptavidin to the CA/PMMA/PEO nanofiber yarns by the photo-reactive crosslinker. This streptavidin was labeled by Alexa Fluor® 594 dye.
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Figure 6. Shown here are results from the immunohistofluorscence study with the
streptavidin-biotin system. (A) Biotinylated bovine anti-mouse IgG, labeled with Alexa
Fluor® 350, and (C) biotinylated mouse anti-FITC IgG, labeled with Alexa Fluor® 594,
functionalized yarns were incubated with mouse-anti-FITC (B), labeled with Alexa
Fluor® 594, and FITC labeled BSA (D), respectively. Control yarns are also shown after
analyte addition.
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The immunohistofluorescence studies showed that the streptavidin-biotin antibody
system could be utilized in the development of the immunoassay systems. It is important
to note that the streptavidin-biotin-mouse anti-FITC functionalized yarn was smaller than
the control yarn, which may initially appear as more fluorescent to the naked eye. The
streptavidin-biotin system could potentially be used to increase the sensitivity of the
immunoassay system or be used in the case of antibodies that lose activity due to
modification by the photo-reactive cross-linker [6].
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Chapter 5
5 Preparation of Gold-labeled Antibody
5.1 Introduction
The synthesis of gold colloid is fairly well known, despite the fact that the
mechanism is still up for debate [118]. Turkevich originally proposed the “organizer
model” for gold nanoparticle nucleation [119]. Other mechanisms proposed include been
the synthesis begins with large particles that shrink with increase reaction time [118,
120], and nanowires smooth to nanoparticles [118, 121] or fragmentation into spherical
nanoparticles with citrate adsorption [118, 122]. The nanoparticles synthesized can be
tailored to narrow size distributions to fit the needs of the application they will be used in.
The most common method is citrate reduction, known as the Turkevich method [119],
where citrate serves as the both the reducing agent and the stabilization agent. Trisodium
citrate dehydrate is added to a boiling solution of HAuCl4 with stirring. The color of the
solution darkens into a deep wine red, which indicates the completed colloid formation
[118, 119, 121, 123-126]. Size of the nanoparticles can be altered by modification of the
reaction conditions such as the pH, temperature, and the concentration of trisodium
citrate and gold [118, 119, 121, 123-126].
Gold has been shown to have an extremely high affinity for protein adsorption
[110]. Gold chips are employed in SPR studies as the substrate to which antibodies are
bound to determine their binding affinity towards antigens [107, 110]. Gold also has a
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very high optical density and has found application in various techniques for labeling
proteins in lateral flow immunoassays and labeling of cellular components in electron
microscopy [127, 128]. Antibodies have frequently been labeled by gold colloid [110,
123, 129]. The proteins bind to the gold nanoparticles by electrostatic and hydrophobic
interactions [129]. Gold colloid will serve as the antibody label used to detect analyte in
our final immunoassay system.
5.2 Materials and Methods
5.2.1

Materials

Bovine anti-mouse IgG and goat anti-rabbit IgG were purchased from SigmaAldrich Corporation. Different gold nanoparticles were used throughout the development
of the immunoassay: 5 nm gold colloid was purchased from British Biocell International
and 25 nm Gold Sol purchased from Aurion.
5.2.2

Preparation of Colloidal Gold-Labeled Antibodies

The goat anti-rabbig IgG antibody to be labeled with gold nanoparticles was purified
by centrifugal filtration and re-suspended in 5 mM sodium bicarbonate (pH 9.0). Purified
goat anti-rabbit IgG was added to stock colloidal gold un-stabilized in water and was
incubated with shaking for 30 minutes at 37° C. To further stabilize and block nonspecific binding of the antibody-gold nanoparticle conjugates, a 10% solution of BSA
was added to bring the conjugates to a final concentration of 1% BSA. The excess protein
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was purified from the conjugates by centrifugation at 5000 rcf for 30 minutes. The fluffy
pellet was then re-suspended in PBS (pH 7.4) with 1% BSA (w/v).
The stabilizing quantity of goat anti-rabbit antibodies required was determined by a
flocculation test performed by a hybrid of flocculation tests performed in industry and
reported in literature and manufacturers [79, 123, 130]. Ratios of antibody molecules per
gold nanoparticle were calculated, 50,100, 150, 200, 250, and 500 antibody molecules per
gold nanoparticle, and added to stock colloidal gold. The solution was vortexed and
incubated at room temperature for 2 minutes. A solution of 10% sodium chloride (NaCl)
was then added to each mixture ratio of antibody molecules to gold nanoparticles. The
absorbance of the colloidal gold labeled antibodies was then measured with a
spectrophotometer. Another flocculation test was performed with the only change being
the incubation condition the antibodies had with the colloidal gold before the addition of
the 10% NaCl solution. The incubation conditions were altered to a 30 minute incubation
period at 37°C with shaking after the addition of the antibodies and vortexing to mix
thoroughly. The 30 minute flocculation test was only performed for the 200 and 500
antibody molecules per gold nanoparticle ratio. The incubation conditions were altered to
allow for sufficient time of antibody adsorption to the gold nanoparticles.
Colloidal gold suspensions are stabilized by the repulsive forces between negatively
charged gold and attractive forces. The addition of electrolytes can interfere with the
negative charge repulsion forces, leading to aggregation of gold nanoparticles [129]. The
presence of enough macromolecules will cause the gold nanoparticles to adsorb to the
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macromolecules, instead of each other, thus preventing aggregation. Aggregation of gold
nanoparticles will cause a shift in the optical density at specific wavelengths [123, 129].
The ratio that did not cause a color change visible by eye or a significant change in the
optical density at 524 nm, the wavelength at which the optical density of stock gold
colloid without salt addition was at a maximum, was chosen and used for all antibodygold nanoparticle conjugate synthesis.
5.3 Results and Discussion
Two different nanoparticle sizes were used throughout the development of the
immunoassay system, 5 nm and 25 nm. These sizes were chosen based on the sizes
reported in literature being typically between 5-50 nm [51, 73-87]. However, the final
size chosen for this immunoassay system was the 25 nm gold nanoparticles, purchased
from Aurion because of their ease of use. Nanoparticles were un-stabilized in water as a
stock solution. This allowed for elimination of the centrifugation step to remove the
stabilizing agents prior to adsorption of antibody. Lower centrifugation speeds could be
used for shorter time periods to purify the nanoparticle conjugates from the excess
unbound antibody. Paramount among the concerns for choosing a nanoparticle size is the
optical signal provided from the nanoparticles in the final immunoassay system. Fewer
nanoparticles of the 25 nm size (

nanoparticles/ml) result in the same optical

density, compared to a larger number (

nanoparticles/ml) of the 5 nm gold

nanoparticles, according to each manufacturer’s lot specifications. Approximately 150X
fewer 25 nm gold nanoparticles could be immobilized at the test and control stripes
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compared to the 5 nm gold nanoparticles, with the same visibility. This leads to a
potential for increasing the sensitivity of the final system by a factor of 150,
approximately.
Stability of the nanoparticle suspensions was checked by dynamic light scattering.
The colloid had a monodisperse combined effective diameter of 34.5 nm, with a mean of
35.7 ± 1.7 nm. The stability of the nanoparticle-antibody conjugates was also evaluated
with a flocculation test and by optical detection of color change. The results from the
flocculation tests are shown below in Figure 7 and Figure 8. The antibody-nanoparticle
ratio chosen for conjugate synthesis was 500 antibody molecules per gold nanoparticle
with the 30 minute incubation at 37°C conditions. At these conditions, no aggregation of
the nanoparticles occurred, as can be observed by no color change detectable by the
naked eye and no change in absorbance at 524 nm. The reference solution was the gold
colloid solution diluted according to the addition of the proteins and salts for the antibody
conjugation test solutions for flocculation. The optical density of the reference solution
was maximized at 524 nanometers, with an average optical density of 0.41367. The
optical density of the 500 antibody molecules per gold nanoparticle solution was 0.41533
as compared to the decrease in optical density of 0.348 for the 200 antibody molecules
per gold nanoparticle ratio. The absorption spectrum of the flocculation tests performed
with the 2 minute and 30 minute incubation conditions are shown below in Figure 7 and
Figure 8, respectively.
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Figure 7.The absorption spectrum of gold colloid solutions after the 2 minute flocculation
test. The control used had ultrapure water added to dilute the sample according to the
dilution resulting from the addition of the antibodies and 10% NaCl added for the test
samples. Antibody was adding according to 50, 100, 150, 200, and 250 antibody
molecules per gold nanoparticle ratio, vortexed and incubated for 2 minutes before the
addition of 10% NaCl.
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Figure 8.The absorption spectrum of gold colloid solutions after the 30 minute
flocculation test. The control was diluted with ultrapure water according to the dilution
resulting from the addition of the antibodies and 10% NaCl added for the test samples.
Antibody was added according to a 200 and 500 antibody molecule per gold nanoparticle
(GNP) ratio, vortexed and incubated for 30 minutes at 37°C for 30 minutes before the
addition of 10% NaCl.
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Chapter 6
6 Development of Immunoassay System
6.1 Introduction
Currently, lateral flow immunoassays (LFIAs) are composed of multiple components.
Generally, these components include a sample pad, a conjugate pad, a reactive zone
membrane, and a reservoir pad. All these components are usually attached to a plastic
backing [8, 10, 12, 51, 54, 77, 79, 80, 88-91, 95, 96]. These components limit the
configuration in which immunoassays can be employed. This can lead to an increased
cost and complexity of manufacturing, and limit the final product configurations of the
lateral flow immunoassays. In some cases, additional components, such as swabs,
reactants, and buffers, are also needed and used in the process of analyzing a sample for
the presence of an analyte. These additional components also lead to additional costs and
can increase the complexity of the immunoassay procedure. The increased complexity of
the procedure can disqualify some immunoassays from being used for over-the-counter,
in-home tests. Limiting the number of components in an immunoassay system can
streamline production time and costs, while limiting the number of steps involved in and
simplifying the procedure and can make immunoassay detection of conditions available
to end-users of varied skill and knowledge levels, allowing for in-home patient use.
While some lateral flow immunoassays can provide excellent sensitivity for a
particular application, others have sensitivities that may be insufficient for some samples.
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Of particular interest for this paper are immunoassays used to diagnose pathogens or
illnesses in patients. Somewhat invasive procedures may be required to retrieve a sample
with sufficient analyte concentration by immunoassays with low sensitivities. For
instance, commonly used CLIA-waived LFIA tests for influenza require the sample to be
collected from nasopharyngeal swabs. Other samples can be used, such as nasal washes
and aspirates, but nasopharyngeal swabs are preferred due to the prevalence of antibody
and antigen available from nasopharyngeal epithelial cells [11, 61-64]. However,
collecting these specimens can be quite uncomfortable and may not be performed by a
patient, themselves. If the sensitivity of immunoassays can be increased, there is potential
for their deployment to aid in the diagnosis of new conditions with lower concentration
analyte or analysis of samples with less concentrated analyte acquired through less
invasive and uncomfortable procedures.
One limiting factor for the sensitivity of an immunoassay is the amount of antibody or
antigen that can be immobilized on the membrane reactive zone. Due to their high
specific surface area, nanofiber yarns can increase the amount of detection molecules
attached to the surface that are able to react with analyte. The unique properties of
nanofiber yarns have found them to be employed in many different fields including:
scaffolds for tissue engineering [131], filtration [132, 133], probes for minute liquid
volumes [112], and colorimetric biosensors [134].
Yarns have several other advantages for employment in biosensor applications. The
nanofiber yarn-based immunoassay can be employed in multiple final device
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configurations. The flexibility of the fibers will allow them to be employed in fabrics
such as panty-liners and facial tissues. Surface modification can be readily accomplished
[134, 135]. Yarn structures can be oriented to have anisotropic flow properties and have
the potential to transport large volumes of fluids [135-137]. The inherent directional flow
characteristics of nanofiber yarns will allow the immunoassay yarn to have uniaxial flow
of sample fluid. This would also allow the nanofiber yarn immunoassay to be included in
facial tissue products, as the analyte will be driven along the longitudinal axis of the
nanofiber yarn rather than out to the surrounding tissue.
6.2 Materials and Methods
6.2.1

Materials

The CA/PMMA/PEO yarns were utilized in the further development of the complete
immunoassay system. The 25 nm Gold Sol purchased from Aurion was used to label the
detection antibodies. The antibody pair chosen for the gold nanoparticles and test and
control lines chosen was the FITC-labeled goat anti-rabbit IgG and the rabbit anti-bovine
IgG purchased from Sigma-Aldrich Corporation. Borosilicate glass fiber conjugate pads
were purchased from EMD Millipore Corporation. Phosphate buffered saline was used at
a concentration of 10 mM. Tween 20 (Acros Organics) was added to the concentrated
noted in some buffers.
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6.2.2

Nanoparticle-Antibody-Analyte Complex Droplet System

Immunoassay yarns and colloidal gold-labeled antibodies were prepared as described
previously. The rabbit anti-bovine IgG analyte was added to the colloidal gold-labeled
goat anti-rabbit IgG, vortexed, and incubated at 37°C for 30 minutes. The end of the
immunoassay yarn was dipped in the resulting droplet of gold nanoparticle-goat antirabbit IgG-rabbit anti-bovine IgG complex. Each end of the yarn was dipped in the
droplet to ensure the nanoparticle conjugates reached both the test and control lines. The
end opposite the nanoparticle droplet was clamped vertically between highly absorbent
tissues acting as a reservoir to provide extra wicking forces. Buffer droplets were also
applied to each end of the yarn after the nanoparticle conjugate droplets to further push
the nanoparticle conjugates along the yarn. A positive result will have two regions of red
coloration, at the test and control antibody stripes approximately 25% of the yarn length
from each end.
6.2.3

Analyte Yarn System

The goat anti-rabbit IgG and the rabbit anti-bovine IgG immobilized during the
preparation of the immunoassay yarn will serve as the test and control stripes for the
immunoassay, respectively. Accumulation of antibody-gold nanoparticle conjugates at
the test and control stripes will result in a positive test. Accumulation of antibody-gold
nanoparticle conjugates at the control line will result in a negative test. Accumulation of
the antibody-gold nanoparticle conjugates at the test stripe only will result in an invalid
test.

53

Rabbit anti-bovine IgG was used as a model analyte for our system. A negative
control immunoassay was also performed using goat anti-mouse IgG analyte at a
concentration of 1 mg/ml. The analyte was added to soak the entire immunoassay yarn
for 30 minutes at room temperature. The analyte was then dried by wicking the liquid to a
tissue. A 10 µl droplet of PBS with 0.05% Tween 20 was added to the yarn and wicked
from the immunoassay yarn to a tissue. This procedure was repeated 15 times to ensure
all analyte was washed from the immunoassay yarn and the yarn was dried. A 5 µl
droplet of antibody-gold nanoparticle conjugates was added to the immunoassay yarn and
allowed to incubate at room temperature. Excess antibody-gold nanoparticle conjugates
were wicked away before the yarn dried to prevent non-specific adsorption to the yarn.
This procedure was repeated until bright red stripes were visible at the test and/or control
lines of the immunoassay yarn.
6.2.4

One-step system

Lateral-flow immunoassays contain a conjugate pad component that houses colloidal
gold labeled antibodies in a dehydrated state. Upon addition of sample fluid to the sample
pad, fluid migrates to the conjugate pad and re-suspends the colloidal gold-labeled
antibodies for migration to and reaction at the reactive site on the nitrocellulose
membrane. The housing of these dehydrated nanoparticles allows for use of the system as
a one-step diagnostic tool that is much simpler than the analyte yarn system. A one-step
system decreases the chance of end-user error that could occur from performing several
steps with specific incubation times. In order to implement our fibers into a one-step
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diagnostic tool, the gold nanoparticle-labeled antibodies will need to be loaded in a
dehydrated state to the immunoassay system
6.2.4.1 Dehydrated Nanoparticle Conjugates on Yarn
Several published articles have reported slightly varying nanoparticle-conjugate
dehydration procedures. Components of the buffer used for dehydration generally include
sucrose and Tween 20 in a buffer solution. The composition of the dehydration buffer
varies slightly [72-74]. A hybrid of these procedures will be used to dehydrate the gold
nanoparticles directly to the nanoparticle yarn to retain antibody activity and wickability
of the nanoparticles along the immunoassay yarn to the reactive zones for test and control
antibodies.
Goat anti-rabbit IgG antibody was labeled with 25 nm colloidal gold by physical
adsorption as reported above. The nanoparticle-antibody conjugates were then
centrifuged to a soft pellet at 5000 rcf for 30 minutes. The supernatant was removed and
the nanoparticle conjugates were re-suspended in PBS with 1% BSA, 1% Tween 20, and
5% sucrose. The nanoparticle conjugates were added to the yarn in very small and
concentrated droplets to prevent the wicking of the conjugates along the length of the
yarn. The length of the dehydrated gold conjugate region can be described by the
equation: L= V⁄(επR2 ), where V is the volume of the droplet added to the yarn, ε is the
porosity of the yarn, and R2 is the radius of the yarn. In-between droplet addition, the
yarn was dried at 37°C. After complete addition of all gold nanoparticle-labeled
antibodies, the yarn was desiccated overnight. To re-suspend the gold nanoparticle-
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labeled antibodies droplets of 10 mM PBS buffer and PBS buffer with 0.05% Tween 20
were added to the exact location of the conjugate dehydration. Success in utilizing gold
conjugates dried directly on nanofiber yarns will result from re-suspension and migration
of the conjugates along the length of the yarn after the drying process, as shown by red
coloration of the entire yarn.
A conjugate adsorption experiment was performed to quantify the amount of
conjugates irreversibly adsorbed to the nanofiber yarns. A CA/PMMA/PEO film was
used to model the surface of the nanofiber yarns. The surface area of the films was
measured by Ryan Freed using an interferometer in Dr. Melinda Harman’s lab. The
lateral surface area of the 12 measured samples, or planar window of measurement, was
4.04± 0.01 mm2 on average. This accounts for approximately 5% of the total surface area
of the film sample. The samples were taken in a 3 sample by 4 sample grid to
accommodate for the large scale topographic features relative to the resolution of the
interferometer. Large features were able to be included in this grid so that additional error
was not incurred by taking surface area measurements where all or most samples could
possibly have the same apparent structure, for instance all on the surface of a large
spherical bump or all in the valleys between bumps. The average surface area was used to
extrapolate the surface area during the conjugate adsorption experiment.
Goat anti-rabbit IgG labeled by FITC was then used to study the protein
adsorption to the surface of the CA/PMMA/PEO films. The antibody was diluted to
concentrations of 10, 5, 2.5, 1, 0.5, 0.25, 0.1, and 0 µg/ml in 10 mM PBS from a stock
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solution of 1 mg/ml antibody. The fluorescence intensity each of these antibody
concentrations was measured in triplicate. A polymer film with a lateral surface area of
18 mm2, corresponding to a surface area of approximately 41.5 mm2, was then incubated
with each sample in a 96 well plate for 1 hour at room temperature with shaking. After
the incubation, the polymer films were removed from the antibody solutions and the
fluorescence intensity of the antibody solutions was measured again.
The standard curve was obtained by the fluorescence measurements achieved
prior to antibody adsorption to the films. Using the standard curve, the protein
concentration remaining after adsorption was calculated by the equation,
, where FI is the measured fluorescence intensity and [P] is the protein
concentration remaining in the solution after adsorption. The antibody mass adsorbed to
the protein surface was then calculated and divided by the surface area to determine the
concentration of antibody adsorbed to the surface of each film. This was then used to
develop the Langmuir model of protein adsorption. The adsorption isotherm was
developed by plotting the adsorbed protein concentration against the initial protein
concentration. Next, the equation:

, was plotted to determine

the affinity constant for antibody adsorption. The fraction of protein adsorbed to the film,
ν, in comparison with the maximum amount of protein adsorbed was then calculated and
the inverse, ν-1, was plotted against the inverse of the equilibrium protein concentration,
[Peq]-1, as determined by fluorescence intensity. The slope of the linear fit of this line
results in the value inverse affinity constant, K-1, from which the affinity constant, K, can
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be determined and plugged into the equation:

to determine the Gibb’s

free energy of adsorption.
6.2.4.2 Conjugate Pad Preparation
Borosilicate glass fiber conjugate pads were purchased from EMD Millipore.
Goat anti-rabbit IgG was labeled with gold nanoparticles by the same method as
described above. These gold-labeled antibodies were added to the glass fiber conjugate
pads by a combination of several methods found in literature [77-79]. The fluffy pellet,
however, was re-suspended in PBS with 1% BSA, 1% sucrose, and 0.05% Tween 20 at a
10-fold higher concentration than the stock concentration. This concentration was chosen
to reduce the time required to add the gold nanoparticle-antibody conjugates to the
conjugate pads. The concentrated gold conjugate solution was added to the conjugate
pads. The conjugate pad was dried at 37 °C for 5 minutes after the addition of each
droplet. After nanoparticles were loaded onto the conjugate pads they were dried
overnight in a desiccator. These conjugate pads were used in the following immunoassay
procedures.
Different thicknesses of conjugate pads were used for different immunoassay
systems. For the contact conjugate pad immunoassay, a 1 mm thick conjugate pad was
used. However to enable twisting of the conjugate pad into the immunoassay yarn
structure, much thinner sections of the conjugate pad were required. The typical diameter
of the immunoassay yarns is approximately 500 µm. The standard borosilicate glass fiber
pads with a 1 mm thickness were mounted on a paraffin block. For our application, the
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conjugate pads could not be embedded in the paraffin block, as it may impede migration
of the gold nanoparticle conjugates out of the conjugate pad or affect the dehydration of
the gold nanoparticle conjugates in the pad. To avoid this, a paraffin block was prepared
in a standard way with no conjugate pad. The very top of the paraffin block was then
heated to barely melt the surface by pressing a hot, flat metal stamp against the surface.
The conjugate pad was then pressed gently against the melted surface and cooled. A
microtome (Leica RM 2255) was used to cut 50 µm and 100 µm longitudinal sections
from the standard borosilicate glass fiber pads, ensuring that only sections from near the
front face, opposite the face attached to the paraffin block, were kept for nanoparticle
conjugate loading.
6.2.4.3 Conjugate Pad Contact Immunoassay
An immunoassay yarn was prepared with a goat anti-rabbit IgG test stripe and
rabbit anti-bovine IgG control stripe. The borosilicate glass fiber pad was loaded with
gold nanoparticle labeled goat anti-rabbit IgG and dried as described above. The
conjugate pad was then soaked with rabbit anti-bovine IgG (2.3 mg/ml) in PBS as an
analyte solution. The analyte soaked conjugate pad was pressed against the middle of the
immunoassay yarn between the test and control stripes. The analyte solution resuspended the gold nanoparticle conjugates and allowed the yarn to wick the resuspended gold nanoparticle-antibody-analyte conjugate to be transferred to the yarn and
wicked to the end of the yarn by capillary action.
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6.2.4.4 Conjugate Pad Incorporated Immunoassay Yarn
Gold nanoparticle-labeled goat anti-rabbit IgG was loaded onto the low retention
glass fiber conjugate pads and dried as described previously. The CA/PMMA/PEO
nanofibers were twisted around the conjugate pads to form a yarn with the conjugate pad
located inside the yarn at the approximate mid-point in length. Goat anti-rabbit IgG and
rabbit anti-bovine IgG test and control lines, respectively, were then immobilized, using
the UV-sensitive sulfo-NHS-LC-diazirine cross-linker, approximately 1 cm from the
either end of the conjugate pad. Very small, 10x concentrated antibody droplets activated
with the cross-linker were added at the test and control stripe locations. The small volume
droplets were required to prevent the antibody solution from wetting the conjugate pad,
thereby releasing the nanoparticle conjugates to the immunoassay yarn. The antibodyimmobilized yarn was then blocked with a 5% BSA solution. To prevent the conjugate
pad from being wetted by the blocking solution, the conjugate pad was clamped between
clean delicate task tissues on each side. Each end of the immunoassay yarn was dipped in
a 50 µl droplet of the 5% BSA blocking solution. The capillary pressure of the
immunoassay yarn allowed the blocking solution droplet to be wicked to just before the
conjugate pad location, where excess was absorbed by the delicate task wipe. After the
blocking solution reached its desired height, the blocking reaction was incubated at room
temperature for 1 hour. A schematic of the conjugate pad incorporated immunoassay yarn
system is shown below in Figure 9.
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Figure 9.Schematic of the conjugate pad incorporated immunoassay yarn system. Shown
here is the conjugate pad twisted in between CA/PMMA/PEO fibers. The test antibody
(goat anti-rabbit IgG) and the control antibody (rabbit anti-bovine IgG) are immobilized
on the surface of the yarn. The gold conjugates are gold-labeled goat anti-rabbit IgG to
detect the rabbit anti-bovine IgG analyte in the sample. As the sample droplet is added
the fluid is wicked along the length of the yarn as indicated by the flow direction arrows.
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6.2.4.5 Three Yarn System
After consideration of each of the previous systems, another system was developed to
provide more confirmatory testing. This system involves inclusion of three yarns: a test
yarn which will detect the presence of an analyte in a sample, a positive control yarn
which will detect the gold-labeled antibodies, and a negative control sample which will
not detect the gold-labeled antibodies or the analyte in question. Antibody immobilization
was performed as previously described with the sulfo-NHS-LC-diazirine cross-linker.
However, in this instance entire yarns were coated with each antibody without the need
for the mask. The test yarn was functionalized with goat anti-rabbit IgG antibody. The
positive control yarn was functionalized with rabbit anti-bovine IgG. The negative
control yarn was immobilized with goat anti-mouse IgG. After the blocking step was
performed the yarns were thoroughly washed by wicking 10 mM PBS as previously
described. The test analyte (rabbit anti-bovine IgG) was added to each yarn at a
concentration of 100 µg/ml and incubated at room temperature for 30 minutes without
drying. The yarns were then washed by wicking 10 mM PBS 10 times. Gold-labeled goat
anti-rabbit IgG was then added to each yarn to completely soak the yarn and incubated
for 20 minutes at room temperature without drying. The unbound gold-labeled antibodies
were then washed away by wicking with 10 volumes of 10 mM PBS.
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6.3

Results and Discussion
6.3.4

Nanoparticle-Antibody-Analyte Complex Droplet System

The yarn was not completely wetted by dipping the end of the nanoparticle
droplet at one end. After dipping both ends of the yarn, the location of both the test and
control lines were wetted and red coloration was apparent. Some red coloration was
apparent at the test and control antibody stripe locations, approximately 25% of the yarn
length from each end. Red coloration was also apparent at the end of the yarns.
Background red coloration was also visible.

Figure 10. Results of the nanoparticle-antibody-analyte complex addition immunoassay.
after dipping both ends in nanoparticle droplet and buffer solution. Specific accumulation
at the antibody stripes can be seen at the test and control lines approximately 25% of the
yarn length from each end. Non-specific accumulation also occurred at the ends of the
immunoassay yarn.
The procedure was fairly complex and difficult. Judgment calls had to be made to
switch the immunoassay yarn ends in the nanoparticle droplet. The length of the
procedure required to see adequate results was also longer than 30 minutes, due to the
need to repeatedly add buffer droplets to the end of the yarn to push the nanoparticles to
the antibody stripes for optimal signal.
The red coloration apparent at the test and control lines indicates specific
nanoparticle-antibody-analyte complex accumulation. The red coloration apparent at the
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ends of the yarn indicates non-specific complex accumulation. Because of the significant
amount of background signal from the gold complexes, the accumulation at the test and
control stripes may be difficult for the end-user to interpret. The nanoparticle
accumulation also does not occur in a very sharp and distinct line, as was expected.
These results provide an important proof-of-concept that this immunoassay system
does have potential. However, the results are not very clear without room for
misinterpretation. The procedure is also rather complex and subjective. Confirmation of
specific nanoparticle-antigen-analyte accumulation is also needed. To improve the yarns
for application into the immunoassay, fine tuning of the yarn processing, materials and
conditions needed to be performed, validating each step in the preparation: the
immunoassay yarn recognition and binding of analyte at the test antibody stripe and
binding of the nanoparticle-antibody conjugates to the control antibody stripe and the
analyte bound to the test antibody stripe, thus a new immunoassay system was
introduced.
6.3.5

Analyte Yarn System

Red coloration can be seen at the location of the test and control antibody stripes
on the immunoassay yarn with rabbit anti-bovine positive analyte due to antibody-gold
nanoparticle accumulation. This yields a positive test for our analyte. Red coloration is
visible at only the control stripe location for the immunoassay conducted with the
negative control (goat anti-mouse IgG) analyte. Results are shown below in Figure 11.
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Figure 11. Immunoassay nanofiber yarns with analyte positive sample (top) and analyte
negative sample (bottom). Two stripes of gold nanoparticle-antibody conjugate
accumulation can be seen in the positive analyte yarn and only one stripe of gold
nanoparticle-antibody conjugate accumulation can be seen on the negative control analyte
yarn.
This system was performed to verify activity and efficacy of each individual
component of the immunoassay system. The covalent antibody attachment has previously
been confirmed by fluorescent microscopy; however, the chemical modification by the
photo-reactive cross-linker may inhibit the antibodies’ recognition of antigens. This
system also confirms that the colloidal gold-labeled antibodies are able to recognize the
control (rabbit anti-bovine IgG) antibody immobilized on the yarn, as well as the analyte
(rabbit anti-bovine IgG) bound to the test antibody (goat anti-rabbit IgG) covalently
immobilized to the yarn.
Laboratories currently use multi-step systems to detect the presence of a pathogen,
such as PCR and ELISA. These systems may require expensive equipment to obtain good
results. The point-of-care system proposed here is procedurally similar to the ELISA
technique and requires some technical knowledge or expertise. Those working in a
clinical laboratory setting or in hospitals and doctors office that would perform this assay,
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such as doctors, nurses, and technicians, should possess the knowledge required to
perform and interpret the results of this assay with minimal training. One key advantage
of this system is that no expensive equipment is required to read the signal obtained from
the assay, unlike the PCR, ELISA and immunofluorescence techniques currently used in
clinical laboratories. This dramatically reduces cost and labor time for clinical
laboratories and also allows this system to be utilized at the point-of-care.
It was evident by the test and control assays shown in Figure 11 that results can be
clearly seen using this technique with little chance of misinterpretation for competent
end-users. The procedure is also fairly simple, for clinical laboratory technicians and
specially trained nurses or doctors to operate at the point-of-care. The sample is added to
the immunoassay yarn and incubated for the antibody recognition reaction to take place
and excess is then wicked away. Then, gold nanoparticle conjugates are added to the yarn
to recognize the antibodies on the stripes, and the excess is wicked away. Clear results
were obtained, but the procedure may be too complex for patients with no technical skill
or knowledge to perform the assay as an in-home diagnostic tool. To further simplify the
procedure, a one-step methodology was needed.
6.3.6

Dehydrated Nanoparticle Conjugates on Yarn

Nanoparticle conjugates taken from a reagent that needed to be added in a liquid
state by trained technicians and were instead added to the immunoassay yarn directly in a
dehydrated state. This allows for an immunoassay that only required sample to be added
to the nanoparticle conjugate site. Dark red, nearly black coloration was seen at the center

66

of the yarn after the nanoparticle dehydration procedure. However, the nanoparticle
conjugates did not wick along the length of the yarn upon addition of a buffer solution.
As a result, this immunoassay system is incapable of detecting antigens present in a
sample for analysis. This led to the further investigation into the current LFIA
technologies and incorporation of other components as well as the discovery of a
promising new potential application for a point-of-care diagnostic tool: the introduction
of the borosilicate glass fiber conjugate pad into the immunoassay system.
The conjugate adsorption was then quantified. Measurements of the surface area
taken by the interferometer revealed, on average, that the actual surface area/lateral
surface area ratio was 2.31± 0.08. Three representative images of the surface area
measurements obtained from the interferometer is shown below in Figure 12.
The adsorption isotherm developed during the fluorescently labeled protein
adsorption study is shown below in Figure 13. The concentration of adsorbed protein was
calculated from the fluorescence intensity using the standard curve, resulting in the
equation:

, where FI is the fluorescence intensity and P is the

protein concentration. The fluorescence intensity from the solutions adsorbed to the films
was then measured in triplicate and each set of values was plugged into the above
equation to find the concentration of antibodies remaining in the solution after the
adsorption. This was then used to determine the concentration adsorbed to the surface of
the films, [Γ], by dividing the mass of protein adsorbed by the surface area of each film.
The adsorption isotherm was plotted as the concentration of antibody adsorbed to the
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surface of the films, Γ (µg/cm2), over the initial protein concentration in solution, [P0].
The fraction of the antibody concentrations adsorbed to the films, ν, for each equilibrium
protein concentration was then calculated assuming the maximum possible antibody
concentration was equal to the maximum observed antibody adsorption, [Γ/Γmax]. The
inverse of the fraction of antibody adsorbed, ν-1, was then plotted against the inverse of
the equilibrium protein concentration, [Peq]-1, to determine the inverse of the affinity
constant of antibody adsorption, K-1, by finding the slope of the linear fit. The equation:
, is plotted below in Figure 14, such that

which

is the fraction of protein adsorbed to the film, K is the affinity constant of antibody
adsorption, and [Peq] is the equilibrium protein concentration. The affinity constant, K,
was determined to be (3± 0.4) x 107, with a linear fit R2 value for this determination
being 0.78. This K value seems appropriate as various protein affinities reported for
Nylon-based membranes range from 1 x 104 to 2.5 x 107 [138]. This linear fitting may be
due to the lowest concentration point, where the sensitivity of the instrument may have
not been adequate. The affinity constant was then plugged into the equation:
, where

is the Gibb’s free energy of adsorption, R = 8.314

,T

is the temperature which was 298K, and K is the affinity constant. The results are shown
below in Figure 14. The ΔG for goat anti-rabbit IgG adsorption to the CA/PMMA/PEO
film was determined to be approximately ΔG= -43 ± 0.3 kJ/mole. The results of the
antibody adsorption experiment are summarized in Table 2.The Gibb’s free energy of
antibody adsorption to the films indicates that the antibodies will adsorb to the
CA/PMMA/PEO yarns and may cause the gold-labeled antibodies to stick to the yarn
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when applied directly and dehydrated, thereby preventing migration along the nanofiber
yarns after addition of aqueous analyte solution. This protein adsorption model is not
precise; however it does reveal the expected trend. This model is commonly employed to
study the adsorption of protein to surfaces. Assumptions made here are that the maximum
protein concentration able to adsorb to the film was that of Γmax such that the film was
saturated, and that the protein concentration had reached equilibrium. Actually the film
had likely not completely reached saturation, although from the adsorption isotherm, it
appears as though it may be near saturation. The monolayer antibody adsorption
assumption for this model may be invalid, as multilayer models have been described in
literature that varies the adsorption affinity slightly [138]. Increasing the initial
concentration of antibody in solution may allow for the model to reach saturation and be
further validated. Also important to note is the accuracy of the interferometer
measurements may not be quite adequate for the scale of topographic features on the
film. Another possible reason for inaccuracy is the variability between the surface
topography between polymer films. This could result in higher surface area, thereby
increasing antibody adsorption to the film compared to other films. The result of the
antibody adsorption to CA/PMMA/PEO surfaces is system that will provide invalid
results due to the inability of the gold-labeled antibodies to re-suspend and migrate along
the length of the yarn.
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Figure 12.Three representative images captured by the interferometer. Each image is that
of an average of 4.04 ± .01 mm2 surface area which translates to 9.32± 0.31 mm2 of
actual surface area.
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Figure 13. The antibody adsorption isotherm to the CA/PMMA/PEO films. It is apparent
that increased protein concentration yields increased antibody adsorption. The films may
have nearly reached saturation.
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Figure 14. The plot of the equation
to determine the affinity
constant for antibody adsorption. The affinity constant was found to be 3x107, resulting
in a Gibb’s free energy of adsorption,
. The adjusted R2
value for the linear fit was 0.78.
Table 2. Results from the antibody adsorption experiment. Included are the Gibb’s free
energy, affinity constant and surface area of the films
Antibody Adsorption Results
Film Surface Area (cm2)

0.4

Affinity Constant [K]

(3 ± 0.4) x 107

Gibb's Free Energy of
Adsorption [ΔG] (kJ/mole)

-43 ± 0.3
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6.3.7

Conjugate Pad Contact Immunoassay

After wetting the gold nanoparticle conjugate pads with analyte solution and
pressing them against the nanofiber yarn, gold nanoparticles quickly transferred from the
low-retention glass fiber pads to the nanofiber yarns. The gold nanoparticles were wicked
along the entire length of the immunoassay yarn and red coloration could be seen at 3
locations, as shown below in Figure 15.

Figure 15. Results of the contact conjugate pad immunoassay are shown here. Red
coloration can be seen at 3 locations along the length of the yarn, the location of pressing
the conjugate pad against the yarn (middle) and the location of the goat anti-rabbit IgG
and rabbit anti-bovine IgG immobilization (left and right).
As a proof-of-concept that the nanoparticle conjugates dehydration procedure was
effective and allowed for release from the conjugate pads to the immunoassay yarn, the
contact conjugate pad immunoassay was performed. This system is less complex than the
point-of-care system proposed earlier because fewer steps are performed by the end-user.
The conjugate pad, which is pre-loaded with colloidal gold-labeled antibody, is dipped in
the sample solution to be wetted, and then manually placed in contact against the
immunoassay yarn. Rapid transfer of nanoparticle conjugates to the immunoassay yarn
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was seen and results were evident in seconds. This procedure is very simple with accurate
results and may be performed by patients as an in-home diagnostic tool, however
simplification of the system would allow for less end-user error, whether the user is in a
clinical laboratory or a patient at home. The clarity of the results was also needed to be
improved to remove doubt and the possibility for misinterpretation by the end-user to
meet CLIA-waived testing requirements.
The introduction of conjugate pads allowed for a two-component system where all the
reagents were in a dried state, but did require some manual labor. This system is still
procedurally more complex than current in-home diagnostic tests, such as pregnancy test
[89, 90] and the OraQuick® in-home HIV test, yet have potential for employment in the
in-home diagnostic market should the results be further clarified and easier to interpret.
However, as is true for most products on the market in any industry, the simplest and
most user-friendly products are much preferred by the consumer. To further simplify the
process an immunoassay that requires only the addition of the sample, similar to the
current LFIA in-home diagnostic tests, was pursued.
6.3.8

Conjugate Pad Incorporated Immunoassay Yarn

To make the procedure simpler for the end-user, the conjugate pad was incorporated
into the yarn. The one-step system provided by the loaded conjugate pads twisted in the
nanoparticle yarns achieved the simplicity of the current LFIA technology utilized in
pregnancy tests [89, 90] and the OraQuick® HIV tests, by requiring the user only to add
the sample to the conjugate pad location to obtain results. The results from the control
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conjugate pad immunoassay are shown below in Figure 16. The immunoassay performed
with the negative sample (goat anti-mouse IgG analyte) showed a very bright, sharp, and
distinct nanoparticle accumulation at one stripe location. Red coloration can be seen at
the location of the conjugate pad after sample addition and at the stripe of nanoparticle
accumulation. After wicking excess, unbound nanoparticles away from the immunoassay
yarn with a tissue by wicking, only the specific nanoparticle accumulation at the stripe
remained.

Figure 16. Results of the control immunoassay with the conjugate pad twisted in the
center of the yarn. An immunoassay yarn after addition of a control sample with goat
anti-mouse IgG (1 mg/ml) is shown. The immunoassay yarn is shown sequentially:
before addition of sample (1), after addition of sample (2), and after wicking excess nonspecifically bound nanoparticles via wicking (3).
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Figure 17. Results of the test analyte immunoassay with the conjugate pad twisted in the
center of the yarn. An immunoassay after addition of a sample containing rabbit antibovine IgG (1 mg/ml) is shown. The immunoassay is shown sequentially: before the
addition of sample (1), after addition of sample (2), and after wicking excess nonspecifically bound nanoparticles via wicking (3).

The test sample containing the rabbit anti-bovine IgG analyte showed red coloration
at the conjugate pad location as well as two stripes on either side approximately 1 cm
from the each end of the conjugate pad, as shown in Figure 17.
The borosilicate glass fiber conjugate pads were then sectioned and cut to allow for
twisting of the pads in the nanofiber yarns. The results are also clear and remove the
possibility for misinterpretation by the end-user, as required to achieve CLIA-waived
status and make the immunoassay feasible for patients to use as an in-home diagnostic
tool. These immunoassay yarns could be marketed as is, however, to make the
technology more attractive to the consumer implementation into a more polished final
device or incorporation into a daily-use item such as facial tissue may increase the
market-share captured. It is important to note that there was variability introduced to the
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immunoassay yarn when twisting the conjugate pad in the middle of the yarn. Those with
50 µm sections of conjugate pads introduced fewer issues with uniform thickness and
twist tightness. Additionally, conjugate pads placed in the exact center of the yarn
thickness allowed for the best wicking of nanoparticles along the length of the
immunoassay yarn to the test and control stripes.
6.3.9

Three Yarn System

The results of the three yarn system immunoassay are shown below in Figure 18.
Red coloration can be seen on the test yarn and the positive control yarn, while the
negative control yarn has less red coloration.

Figure 18. Three yarn system. The test yarn (left), positive control yarn (middle), and
negative control yarn (right) after the immunoassay.
This system allows for a distinct result; however, there is skill involved at the
same level as the analyte yarn system mentioned previously. This three yarn system may
be more attractive to point-of-care facilities due to the additional confirmatory yarn that
further validates results. It may also be twisted into a triple-yarn system for in-home
diagnostics in the future or oriented in a geometric configuration, such as a triangle or a
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parallel array, in daily use items such as facial tissues or panty liners. This would allow
for patients to have immediate diagnosis of conditions, such as influenza and HIV, prior
to symptom development. This would allow for the earliest possible detection of the
condition.
6.3.10 Cost Analysis
A major advantage of the nanofiber-based immunoassay system is the potential for
reduction in cost of manufacture of these devices for point-of-care and in-home use. This
reduction in cost would increase the availability of the test to those with low income or in
low-resource settings, such as third world countries and prison systems. Cost reduction
may come from a reduction in the raw materials used and a cheaper manufacturing cost.
The yarn systems will use fewer components. The sample pads and absorbent pads used
in the current lateral flow immunoassay systems will not be used; the components will
not require the plastic backing all the components are assembled on. Rather than use the
nitrocellulose membranes, the yarn system will utilize the polymer yarns, which may be
easier to manufacture. Smaller conjugate pads are used in the system allowing for cost
saving as well. The conjugate pads employed in the yarn systems are 20 times thinner
than with a 10 times smaller in the length and width dimensions. Table 2 provides a
comparison between the current technology and the conjugate pad incorporated yarn
system (the most expensive of these proposed systems) raw materials cost. Excluded
from this analysis are the costs of the gold nanoparticles and antibodies. These costs
would also be reduced due to the increased loading efficiency of the antibody on the
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nanofiber yarns via covalent cross-linking. Packaging costs used in the analysis refer to
the individual foil packaging of each current lateral flow immunoassay, which may not be
necessary for the fiber system. The antibody estimate assumes that the fibers based
system will allow for a 10% increase in antibody loading efficiency with the cross-linker
from a 4-5 µg antibody loading. It is important to note that the cross-linker cost may be
reduced with larger scale production. In addition to the raw materials savings,
manufacturing cost are predicted to decrease due to the fewer components. Machinery
will be eliminated, energy costs may be reduced, personnel costs would be reduced, and
the time to manufacturing time should be reduced due to the fewer steps involved in
component manufacture and assembly time. These factors combined lead to the potential
for a cheaper diagnostic test platform that will increase availability, thus allowing more
patients to seek the appropriate medical care.
Table 3. The raw materials cost comparison between the yarn system and the current
lateral flow immunoassay yarn systems.
Cost ($) of Raw Materials Per Immunoassay
Component
Yarn
Conjugate Pad
Sample Pad
Nitrocellulose Membrane
Absorbent Pad
Plastic Backing
Cassette
HIV Antibody Estimate
Cross-linker
Total
Savings

Commercial LFIA
0
0.005
0.004
0.009
0.004
0.009
0.4
11.88-14.85
0
12.33-15.30
-
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Yarn System
0.04
0.000025
0
0
0
0
0
10.69-13.37
0.61
11.34-14.02
.99-1.28

Chapter 7
7 Conclusions & Further
Recommendations
7.1 Conclusions
It was determined that the CA/PMMA/PEO fiber composition was the best-suited for
the application in an immunoassay yarn. This composition allows for sufficient antibody
binding as determined by fluorescence microscopy. It also allows for sufficient wicking
of the nanoparticle conjugates along the length of the yarn of any configuration.
The porosity and permeability of the yarns are appropriate to provide excellent
wicking properties in our immunoassay system. While yarns of all compositions tested in
this work allowed for sufficient antibody binding using the photo-reactive cross-linker,
the CA/PMMA/PEO composition was the most appropriate for the wicking of the
nanoparticle conjugates. The antibody immobilization technique also retained the
antibody activity in the system with and without the streptavidin-biotin reaction. The gold
nanoparticles offer appropriate size and antibody adsorption characteristics for
employment in our immunoassay system.
The immunoassay systems developed throughout this work show promise for
application in the field of diagnostics. The point-of-care system could be used in clinical
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laboratories or at the point-of-care with minimal training. The gold nanoparticle
conjugates cannot be loaded as a dry-reagent directly to the nanofibers, due to protein
adsorption. This does not allow for the one-component system that is desired. However,
borosilicate conjugate pads can be employed to simplify the procedure compared to the
point-of-care immunoassay. The contact conjugate pad immunoassay system could also
be employed in the clinical laboratory or point-of-care settings. A major void in the
market is that of one-step, in-home diagnostic tests. The conjugate pad incorporated
immunoassay system could be used as an in-home diagnostic tool, due to its ease of use
and little chance for misinterpretation. The three yarn system could be used at the pointof-care and potentially employed for at home use. This system could also further reduce
the cost of the immunoassay system by using fewer raw materials. The yarn systems also
allow for greater than 10 times lower raw materials cost and potentially reduced
manufacturing cost.
7.2 Further Recommendations
Wicking properties of the immunoassay yarns may be increased by increasing the
hydrophilicity of the fibers. The sensitivity of the immunoassay system is extremely
important to determine its successful employment as a diagnostic tool. Studies still need
to be conducted on these systems to determine if clinically relevant analyte
concentrations can be detected, as a model-system initially, and eventually using clinical
samples. Should the current immunoassay method not be sufficient, introduction of the
streptavidin-biotin system could increase the sensitivity efficiently. Silver-amplification
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methods have also been shown effective in increasing the sensitivity of the
immunochromatographic assays. This adds complexity and expense to the immunoassay,
but may be a viable way to increase the sensitivity of the system for use in a clinical
laboratory or point-of-care setting.
It is important to note that the increase of hydrophilicity may allow for an even
simpler system, where there is no conjugate pad needed to release the nanoparticles.
Increasing the hydrophilicity will more closely mimic the borosilicate glass fiber
conjugate pad employed in the immunoassay. Incorporating poly(glycidyl methacrylate)
(PGMA) or increasing the composition of PEO in the yarn may increase the
hydrophilicity enough to lower the binding affinity of the yarn sufficiently and allow the
nanoparticle conjugates to be dried on the nanofiber yarn in the same manner as they are
dried on the conjugate pad. This will make the production of the immunoassay much
simpler and may increase the wicking properties from the dried conjugate area, as the
interfiber distances will be smaller without the disruption caused by the conjugate pad.
This would also eliminate a component utilized in the immunoassay, reducing cost for the
final product.
The point-of-care system and the contact conjugate pad system can be modified to be
implemented in a high-throughput procedure. This would be advantageous for clinical
laboratories that receive large volumes of samples for analysis to improve the turnaround
time and diagnosis or confirmation for the patient. This could be accomplished by
implementing manual devices similar to multi-channel pipettes and 96-well plates
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commonly used for ELISA techniques. Automated equipment could also be implemented
to enhance the amount of samples that can be analyzed. This would also reduce
variability in results that may be obtained and eliminate the possibility of end-user error.
After processing of the samples, the results could then be read by laboratory technicians
to be reported back to the attending physicians and patients. The equipment required for
this automated technique would only be appropriate for clinical laboratories that receive
large quantities of samples for analysis from multiple centers for patient care.
Automated or higher-throughput preparation of the immunoassay yarns for point-ofcare application, contact conjugate pad immunoassays, or in-home diagnostic tests should
also be realized prior to marketing of the devices. This would decrease the possibility for
variability between tests that may be introduced by different immunoassay production
personnel or the same individual; thereby increasing quality and uniformity of the endproduct.
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